A short review: Doxorubicin and its effect on cardiac proteins
| dc.contributor.author | Upadhyay, Shishir | |
| dc.contributor.author | Gupta, Kunj Bihari | |
| dc.contributor.author | Mantha, Anil Kumar | |
| dc.contributor.author | Dhiman, Monisha | |
| dc.date.accessioned | 2024-01-21T10:44:34Z | |
| dc.date.accessioned | 2024-08-13T13:22:19Z | |
| dc.date.available | 2024-01-21T10:44:34Z | |
| dc.date.available | 2024-08-13T13:22:19Z | |
| dc.date.issued | 2020-12-26T00:00:00 | |
| dc.description.abstract | Doxorubicin (DOX) is a boon for cancer-suffering patients. However, the undesirable effect�on health on vital organs, especially the heart, is a�limiting factor, resulting in an increased number of patients with cardiac dysfunction. The present review focuses on the contractile machinery and associated factors, which get affected due to DOX toxicity in chemo-patients for which they are kept under life-long investigation for cardiac function. DOX-induced oxidative stress disrupts the integrity of cardiac contractile muscle proteins that alter�the rhythmic mechanism and oxygen consumption rate of the heart. DOX is an oxidant and it is further discussed that oxidative stress prompts the damage of contractile components and associated factors, which include Ca2+ load through Ca2+ ATPase, SERCA, ryanodine receptor-2, phospholamban, and calsequestrin, which ultimately results in left ventricular ejection and dilation. Based on data and evidence, the associated proteins can be considered as clinical markers to develop medications for patients. Even with the advancement of various diagnosing tools and modified drugs to mitigate DOX-induced cardiotoxicity, the risk could not be surmounted�with survivors of cancer. � 2020 Wiley Periodicals LLC | en_US |
| dc.identifier.doi | 10.1002/jcb.29840 | |
| dc.identifier.issn | 7302312 | |
| dc.identifier.uri | http://10.2.3.109/handle/32116/3792 | |
| dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/jcb.29840 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Wiley-Liss Inc. | en_US |
| dc.subject | cardiac contractility | en_US |
| dc.subject | cardiotoxicity | en_US |
| dc.subject | doxorubicin | en_US |
| dc.subject | oxidative stress | en_US |
| dc.title | A short review: Doxorubicin and its effect on cardiac proteins | en_US |
| dc.title.journal | Journal of Cellular Biochemistry | en_US |
| dc.type | Review | en_US |
| dc.type.accesstype | Closed Access | en_US |